Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin and CBS domain divalent metal cation transport mediator 3 (CNNM3)
- Target
- CNNM3
- Molecular classification
- Transporter, Metal transporter, CBS domain-containing protein
01
Overview
CNNM3 encodes a membrane protein with four transmembrane domains, two CBS (Cystathionine beta-synthase) domains, a DUF21 domain, and a cyclic nucleotide monophosphate (cNMP)-binding domain. It most likely functions as a transporter of divalent metal cations, especially magnesium, across cellular membranes, playing a critical role in magnesium ion homeostasis. It interacts with the TRPM7 channel to stimulate divalent cation entry into cells. Diseases associated with CNNM3 include Jalili Syndrome and Fanconi Anemia. This protein is conserved across vertebrates, highlighting its importance in physiology.
- Other names
- Cyclin-M3ACDP3 (Ancient conserved domain protein 3)
02
Mechanism of action
Drugs that modulate divalent cation (particularly magnesium) transport or affect channel interactions (such as blocking TRPM7 interaction, or altering magnesium homeostasis)
03
Biological functions
Magnesium ion homeostasisTransmembrane transporter activityDivalent cation transport (notably Mg²⁺)
04
Disease associations
Jalili SyndromeFanconi Anemia, Complementation Group CPotential involvement in various developmental and metabolic disorders
05
Safety considerations
Disturbance of magnesium ion homeostasis can result in broad metabolic and neurological effectstargeting CNNM3 may risk electrolyte imbalance or related adverse effects
06
Interacting drugs
Inhibition of divalent cation transport (especially magnesium)
1 more in the full profile.
07
Biomarkers
None explicitly listed in major public databases; further research is required to confirm CNNM3 as a patient selection or efficacy biomarker
Beyond the preview
Go deeper on Cyclin and CBS domain divalent metal cation transport mediator 3 (CNNM3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclin and CBS domain divalent metal cation transport mediator 3 (CNNM3).